An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33154106.
- Also identified by DOI 10.1126/science.abe3255 and PMC identifier 7857409.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus enters host cells via an interaction between its Spike protein and the host cell receptor angiotensin-converting enzyme 2 (ACE2). By screening a yeast surface-displayed library of synthetic nanobody sequences, we developed nanobodies that disrupt the interaction between Spike and ACE2. Cryo-electron microscopy (cryo-EM) revealed that one nanobody, Nb6, binds Spike in a fully inactive conformation with its receptor binding domains locked into their inaccessible down state, incapable of binding ACE2. Affinity maturation and structure-guided design of multivalency yielded a trivalent nanobody, mNb6-tri, with femtomolar affinity for Spike and picomolar neutralization of SARS-CoV-2 infection. mNb6-tri retains function after aerosolization, lyophilization, and heat treatment, which enables aerosol-mediated delivery of this potent neutralizer directly to the airway epithelia.
Medical subject headings
- Antibodies, Neutralizing
- Antibodies, Viral
- Single-Domain Antibodies
- Spike Glycoprotein, Coronavirus